Background. The outlook for many brain tumors remains poor. Increased dose intensity has been correlated with response rate and survival in many solid tumors.
Patients and Methods. Ten children with recurrent or newly diagnosed brain tumors were treated with four sequential courses of highdose single agent chemotherapy with peripheral blood stem cell (PBSC) support. PBSC harvesting was undertaken prior to chemotherapy and following the first course of chemotherapy (3.6 g/m 2 etoposide). Each course of chemotherapy consisted of a single drug followed 48 hours later by PBSC reinfusion. Three patients were treated on Regimen A: etoposide, carboplatinum 1.95 g/m 2 , cyclophosphamide 5 g/m 2 , and thiotepa 300 mg/m 2 ; three patients were treated on Regimen AΠ with carmustine 600 mg/m 2 replacing cyclophosphamide; four patients received Regimen B: etoposide, carboplatinum 1.95g/m 2 , cyclophosphamide 7 g/m 2 , and thiotepa 900 mg/m 2 .
Results.
No course of chemotherapy was complicated by >14 days of neutropenia. Platelet recovery was more prolonged, particularly in patients who had previously received craniospinal irradiation. Non-hematologic toxicity was severe with three toxic deaths including two patients who developed hemolytic-uremic syndrome and respiratory failure. Two of three patients with primitive neuroectodermal tumors had a partial response; no responses were observed in patients with high-grade gliomas.
Conclusions. Administration of multiple courses of high-dose chemotherapy with PBSC support is feasible in this patient population and successfully mitigates hematologic toxicity. Non-hematologic toxicity becomes prohibitive as chemotherapy doses are escalated. Med. Pediatr. Oncol. 29:553-559, 1997.